CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital

RBC Capital analyst Luca Issi lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $60.00 (from $66.00) while maintaining a Sector Perform rating.

The analyst comments "Casgevy’s launch is under way with >35 ATCs activated (vs >25 last Q) and cells collected from 20 patients (vs 5 last Q). In oncology, first look at next-gen CD19 for NHL is expected later this year. In autoimmune, lupus trial is now open. On in vivo, ANG3 and Lpa are in Phase I. Overall, we appreciate all the progress, but we remain on the sidelines, as we are cautious on Casgevy’s launch and awaiting further progress on the rest of the pipeline. We lower the PT from $66 to $60 to reflect the Q."

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• BofA says CTA Treasury shorts stable, euro short-cover risk rises